Dokumentdetails
ID

doi:10.1186/s13041-021-00787-6...

Autor
Magota, Hirotoshi Sasaki, Masanori Kataoka-Sasaki, Yuko Oka, Shinichi Ukai, Ryo Kiyose, Ryo Onodera, Rie Kocsis, Jeffery D. Honmou, Osamu
Langue
en
Editor

BioMed Central

Kategorie

Neurology

Jahr

2021

Auflistungsdatum

08.12.2022

Schlüsselwörter
amyotrophic lateral sclerosis mesenchymal stem cells intravenous... multiple doses quality of life deterioration function single als compared motor
Metrisch

Zusammenfassung

Amyotrophic lateral sclerosis (ALS) is a neurodegenerative fatal disorder in which motor neurons within the brain and spinal cord degenerate.

A single infusion of mesenchymal stem cells (MSCs) delays disease progression by protecting motor neurons and restoring the blood-spinal cord barrier in the SOD1G93A transgenic ALS rat model.

However, the therapeutic effect of a single infusion of MSCs is transient and does not block disease progression.

In this study, we demonstrated that repeated administration of MSCs (weekly, four times) increased the survival period, protected motor functions, and reduced deterioration of locomotor activity compared to a single infusion and vehicle infusion, after which rats displayed progressive deterioration of hind limb function.

We also compared the days until gait ability was lost in rats and found that the repeated-infused group maintained gait ability compared to the single-infusion and vehicle-infusion groups.

These results suggest that repeated administration of MSCs may prevent the deterioration of motor function and extend the lifespan in ALS.

Magota, Hirotoshi,Sasaki, Masanori,Kataoka-Sasaki, Yuko,Oka, Shinichi,Ukai, Ryo,Kiyose, Ryo,Onodera, Rie,Kocsis, Jeffery D.,Honmou, Osamu, 2021, Repeated infusion of mesenchymal stem cells maintain the condition to inhibit deteriorated motor function, leading to an extended lifespan in the SOD1G93A rat model of amyotrophic lateral sclerosis, BioMed Central

Dokumentieren

Öffnen

Teilen

Quelle

Artikel empfohlen von ES/IODE AI

Systematic druggable genome-wide Mendelian randomization identifies therapeutic targets for lung cancer
agphd1 subtypes replication hykk squamous cell gene carcinoma causal targets mendelian randomization cancer analysis